AilseBio is a biotech company advancing cancer immunotherapy through AI-driven antigen discovery. Its proprietary TiNA Discovery platform identifies novel, therapy-induced antigens-unlocking a new class of targets for next-generation cancer vaccines and cell therapies.
Founded in 2021 and based in Belfast, AilseBio is a spin-out supported by Queen’s University Belfast and part of the QUBIS portfolio. By uncovering hidden antigens missed by traditional approaches, AilseBio enables more precise, personalised immuno-oncology treatments.
Focus areas:
- Immuno-oncology: solid tumours and haematological cancers
- AI-powered target discovery for cancer vaccines and cell therapies
- Proprietary TiNA (Therapy-induced NeoAntigen) technology platform